Speaker(s): 

Duncan Dobbins, PharmD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Eric Wright, PhD, MPH, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the role and purpose of Preferred Drug Lists (PDLs) within Medicaid and their impact on drug accessibility.
• Use the CMS Open Payments program to find financial relationships tracked between pharmaceutical companies and healthcare providers.
• Analyze the influenceof pharmaceutical payments on prescribing behaviors and potential conflicts of interest within Medicaid PDL selection committees.
• Evaluate the ethical implications of pharmaceutical payments on PDL decision-making and explore potential future directions for policy and research on managing conflicts of interest.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.